Craig-Hallum Starts PepGen Inc. (PEPG) at Buy, PT $11

Craig-Hallum analyst Adam Vogel initiates coverage on PepGen Inc. (NASDAQ: PEPG) with a Buy rating and a price target of $11.00.

The analyst comments "We view PGN-EDODM1 as a high-risk but highly asymmetric myotonic dystrophy type 1 recovery story with the potential for 7-8x upside if higher-dose data validate the early clinical signal. With shares trading at below cash, little-to-no value is being assigned to PEPG’s lead DM1 program, EDO platform optionality, nor the possibility that upcoming clinical data can reframe the story. At current levels, the bar is low enough that cleaner higher-dose DM1 data could drive a meaningful recovery trade."

For an analyst ratings summary and ratings history on PepGen Inc. click here. For more ratings news on PepGen Inc. click here.

Shares of PepGen Inc. closed at $1.53 yesterday.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Groq raises $650m to expand AI inference cloud operations
• BuzzFeed sells shares to Byron Allen affiliate for $5.8 million